Despite repeated outbreaks and alarmingly high death rates, the world still lacks approved vaccines for some of the deadliest viruses known to humans—among them Nipah virus. With fatality rates reaching up to 75% in past outbreaks, the absence of a preventive vaccine raises a troubling question: why has science not yet delivered protection against such lethal pathogens?
The answer lies at the intersection of science, economics, ethics, and global health priorities.
Nipah virus is classified as a priority pathogen by the World Health Organization because of its ability to cause severe disease, its high mortality rate, and the lack of approved medical countermeasures. The virus can cause acute respiratory illness, brain inflammation (encephalitis), and long-term neurological damage among survivors.
Outbreaks have occurred sporadically, mainly in South and Southeast Asia, often linked to zoonotic transmission from fruit bats and, in some cases, human-to-human spread. While outbreaks tend to be limited in size, their severity makes them particularly dangerous.
Yet, more than two decades after the virus was first identified, no licensed vaccine exists for public use.
Scientific challenges: studying a rare but lethal disease
One of the biggest obstacles to vaccine development for Nipah is the sporadic nature of outbreaks. Unlike diseases such as influenza or COVID-19, Nipah does not cause widespread, continuous transmission. This makes it extremely difficult to conduct large-scale clinical trials needed to test vaccine efficacy.
To approve a vaccine, regulators typically require:
- Clear evidence of safety
- Proof that the vaccine prevents disease
- Data from thousands of participants
For Nipah, outbreaks are unpredictable, geographically limited, and often contained quickly through public health measures. This means there are not enough cases to run traditional Phase 3 efficacy trials, a key step in vaccine approval.
Ethical barriers to human trials
Ethical constraints further complicate progress. Unlike mild or moderately severe diseases, Nipah infection carries a high risk of death or permanent disability. This makes human challenge trials—where volunteers are deliberately exposed to a virus—ethically unacceptable.
As a result, researchers must rely heavily on animal models to study immune responses and protection. While animal studies have shown promise, translating these results into guaranteed human protection is scientifically complex and slow.
International initiatives aim to bridge the gap. Coalitions involving governments, research institutions, and philanthropic organisations are working to fund vaccine platforms for high-risk pathogens before they cause pandemics.
Experts argue that platform-based vaccine technologies—where a proven system can be rapidly adapted to new viruses—offer the best hope for diseases like Nipah. The success of mRNA vaccines during COVID-19 has renewed optimism in this approach.
Why this matters beyond NipahNipah is not an isolated case. Several other high-fatality viruses—such as certain hemorrhagic fevers—also lack approved vaccines. The same barriers apply across this category of pathogens.Public health experts warn that any one of these viruses could adapt for wider human transmission, with devastating consequences.
The takeaway
The absence of vaccines for high-fatality viruses like Nipah highlights a fundamental weakness in global health systems: the world is better at reacting to pandemics than preventing them.
